Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Adds To Diabetes Franchise With SmartCells Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck announced Dec.2 that it is acquiring privately-held SmartCells for the company's preclinical SmartInsulin diabetes program in a deal potentially worth as much as $500 million. The acquisition will help bolster sales of Merck's blockbuster diabetes drug Januvia.
Advertisement

Related Content

Taking Wing With Biotech Angel Investors
Merck-Geisinger Collaboration Aims For “Pipeline” Of Treatment Adherence Tools
Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
Sanofi-AgaMatrix Deal a Harbinger

Topics

Advertisement
UsernamePublicRestriction

Register

PS071558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel